March 2011

Stover KR, Cleary JD. Use of Echinocandins for Candida parapsilosis Infections
commenting on Kale-Pradhan PB, Morgan G, Wilhelm SM, Johnson LB. Comparative efficacy of echinocandins and nonechinocandins for the treatment of Candida parapsilosis Infections: a metaanalysis. Pharmacotherapy 2010;30(12):1207–13.

Peeters MJ, Rivera CG. Biostatistics and Parametrics
commenting on Kier KL. Biostatistical applications in epidemiology. Pharmacother 2011;31(1):9–22.

Tillman EM, Caudle KE. Training Pathways for Clinical Pharmacy Investigators: Pharm.D.-only or Pharm.D./Ph.D.: The Trainee’s Perspective

February 2011

Van Lieshout RJ, Lalonde CD.Trials of Adjunctive Atypical Antipsychotics for Treatment Resistant Generalized Anxiety Disorder Not Located by a Medline Search
commenting on Lorenz RA, Jackson CW, Saitz M. Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder. Pharmacotherapy 2010;30(9):942–51.

December 2010

Riche DM, Call, RJ. PPIs and Plavix: So, What To Do Now?
commenting on Kreutz RP, Stanek EJ, Aubert R, et al. Impact of Proton Pump Inhibitors on the Effectiveness of Clopidogrel After Coronary Stent Placement: The Clopidogrel Medco Outcomes Study. Pharmacotherapy. 2010;30(8):787-96.

October 2010

Bunce CP, Lock JL, Patel RK . Comparison of Clinically Significant Cardiovascular Events Between Three Fluoroquinolones
commenting on Li EC, Esterly JS, Pohl S, Scott SD, McBride BF. Druginduced QT-Interval Prolongation: Considerations for Clinicians. Pharmacotherapy 2010;30(7):684–701.

September 2010

Tsai H-C, Lee SS-J, Chen Y-S. Comment on Oral Doxycycline for Treatment of Neurosyphilis in Two Patients Infected with Human Immunodeficiency Virus
commenting on Kang-Birken SL, Castel U, Prichard JG. Oral doxycycline for treatment of neurosyphilis in two patients infected with human immunodeficiency virus. Pharmacotherapy. 2010;30(4):119e–22e

Oshikoya KA, Adefurin AO: Drug Induced Hepatotoxicity in a 9-Year-Old Boy: Possible Cause is Cotrimoxazole, Acetaminophen or Both Medicines
commenting on Bell TL, Foster JN, Townsend ML. Trimethoprimsulfamethoxazole-induced hepatotoxicity in a pediatric patient. Pharmacotherapy. 2010;30(5):539

June 2010

Sejnowski CA: Pharmacists Initiatives at Chronic Disease State Management
commenting on Carter BL, Doucette WR, Franciscus CL, Ardery , KluesnerKM, Chrischlles EA. Deterioration of Blood Pressure Control After Discontinuation of a Physician-Pharmacist Collaborative Intervention. Pharmacotherapy 2010;30(3):228-235.

May 2010

Figg, WD: When Does a Malpractice Error Become a Felony?

March 2010

Cook GE, Sukkari SR, Sasich LD: An Additional Source of Bias in Antidepressant and Other Trials
commenting on Woolley SB, Cardoni AA, Goethe JW. Last-observation carried-forward imputation method in clinical efficacy trials: review of 352 antidepressant studies. Pharmacotherapy 2009;Dec 29(12):1408-16.

September 2009

Riche DM, Pierce WA, King ST: Vitamin D and Cardiovascular Disease: A Second Look
commenting on Nemerovski CW, Dorsch MP, Simpson RU, Bone HG, Aaronson KD, Bleske BE. Vitamin D and cardiovascular disease. Pharmacotherapy 2009;29(6):691-708.

June 2009

Hu M, Tomlinson B. Rhabdomyolysis Caused by a Potential Sitagliptin-Lovastatin Interaction – What about the Diltiazem?
commenting on DiGregorio RV, Pasikhova Y. Rhabdomyolysis Caused by a Potential Sitagliptin-Lovastatin Interaction. Pharmacotherapy 2009;29(3):352-356.

May 2009

Backes JM, Ruisinger JF, Moriarty PM. Sitagliptin-Lovastatin and Possible Rhabdomyolysis: Correlation and Mechanism Unknown
commenting on DiGregorio RV, Pasikhova Y. Rhabdomyolysis Caused by a Potential Sitagliptin-Lovastatin Interaction. Pharmacotherapy 2009;29(3):352-356.

March 2009

LeClaire AC, Caruso LJ. Effect of Intravenous Propacetamol on Blood Pressure in Febrile Critically Ill Patients – An Alternative Viewpoint
commenting on Hersch M, Raveh D, Izbicki G. Effect of intravenous propacetamol on blood pressure in febrile critically ill patients. Pharmacotherapy 2008;28(10):1205–10.

White CM. Clinical Scientist Ph.D. Program Panacea: Where’s The Data?
commenting on Dowling TC, Murphy JE, Kalus JS, et al. Recommended education for pharmacists as competitive clinical scientists. Pharmacother 2009;29(2):236–44.

January 2009

Tebbe SR. Conflicting Data: Association of Proton Pump Inhibitors and Risk of Osteoporotic Fractures
commenting on Kaye JA and Jick H. Proton Pump Inhibitor Use and Risk of Hip Fractures in Patients without Major Risk Factors. Pharmacotherapy 2008;28(8):951-959.

October 2008

Wargo KA. Clincial Judgment: To Renal Dose Adjust Antimicrobials or Not
commenting on Golik MV, Lawrence KR. Comparison of dosing recommendations for antimicrobial drugs based on two methods for assessing kidney function: Cockcroft-Gault and Modification of Diet in Renal Disease. Pharmacotherapy 2008;28(9):1125-1132.

Hunt J. The Future of Advanced Pharmacy Practice: Wildcats versus Zeroes

September 2008

Ambrosini MT. Autoimmunity and Schizophrenia
commenting on Goldsmith CW, Rogers DP. The Case for Autoimmunity in the Etiology of Schizophrenia. Pharmacotherapy 2008;28(6):730-741.

Csajka C, Cavassini M, Rotger M, et al. Efavirenz Dose Adjustment in HIV Patients with Impaired CYP2B6 Function
Commenting on Torno MS, Witt MD, Saitoh A., et al. Successful use of reduced-dose efavirenz in a patient with human immunodeficiency virus infection: Case report and review of the literature. Pharmacotherapy 2008;28(6):782-787.

July 2008

Clay PG. Research Publications by Pharmacists: Kudos and Questions
commenting on Touchette DR, Bearden DT, Ottum SA. Research publications by pharmacist authors in major medical journals: changes over a 10-year interval. Pharmacotherapy 2008;28(5):584-90.

April 2008

Ensom RJ, Ensom MHH. Will Genetic Testing for Warfarin Dosing Ever Be Ready for Prime Time?
commenting on Bussey HI, Wittkowsky Ak, Hylek EM, Walker MB. Genetic testing for warfarin dosing? Not yet ready for prime time. Pharmacotherapy 2008:28(2):141-3.

March 2008

Leung S, Poulakos MN, Ramirez-Ruiz L. Comparing Unbound Plasma Posaconazole Levels to Fungal Minimal Inhibitory Concentrations (MICs) in Allogenic Hematopoietic Stem Cell Transplant (HSCT) Recipients with Graft-Versus-Host Disease (GVHD)
commenting on Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. Pharmacokinetics of oral Posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 2007;27(12):1627-36.

Marrs JC, Saseen JJ. Debating the Clinical Benefits of Ranolazine and its Role in Therapy
commenting on Dobesh PP, Trujillo TC. Ranolazine: a new option in the management of chronic stable angina. Pharmacotherapy 2007;27(12):1659-76.

February 2008

Mascitelli L, Pezzetta F, Goldstein MR. Statin Therapy and Intracerebral Hemorrhage
commenting on Weant KA, Cook AM. Potential roles for statins in critically ill patients. Pharmacotherapy 2007;27(9):1279-96.

January 2008

Gerhard T, Zineh I, Winterstein AG, Hartzema AG. Uncertain Economic Impact of Nesiritide in Advanced Decompensated Heart Failure
commenting on Munger MA, Ng TM, Van Tassell BW. Controversy and conflict in the treatment of acute decompensated heart failure: nesiritide as evidence-based treatment. Pharmacotherapy. 2007;27(5):619-625.

Leung S, Poulakos MN, Kernan W. Is the Drug Interaction Actual between Posaconazole and Cyclosporine?
commenting on Sansone-Parsons A, Krishna G, Martinho M, Kantesaria B, Gelone S, Mant TG. Effect of posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 2007;27(6):825-34.

Doloresco F, Vermeulen LC. Insufficient Evidence of Equivalence—Alternate Dosing of Meropenem
commenting on Patel GW, Duquaine SM, McKinnon PS. Clinical Outcomes and Cost Minimization with an Alternative Dosing Regimen for Meropenem in a Community Hospital. Pharmacotherapy 2007;27(12):1637-43.

September 2007

Slavik RS, Gorman SK. Error Rates Among Clinical Pharmacists in Calculating the APACHE II Score
commenting on Greenwood B, Szumita PM, Levy H, Lilly CM. Error rates among clinical pharmacists in calculating the APACHE II score. Pharmacotherapy 2007;27(2):285-289.

Bantar C. Tigecycline: Searching the Rationale to the Enforced Off-Level Usage
commenting on Reid GE, Grim SA, Aldeza CA, Janda WM, Clark NM. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 2007;27:1198–1201.

August 2007

Schwenk MH. Safe Administration of Iron Sucrose in a Patient with a Previous Hypersensitivity Reaction to Ferric Gluconate—Comment
commenting on Sane R, Baribeault D, Rosenberg CL. Safe administration of iron sucrose to a patient with a history of previous hypersensitivity reactions to sodium ferric gluconate. Pharmacotherapy 2007;27(4):613–615.

July 2007

Faus MJ, Sabater-Hernándex D, Amariles P. Types of Pharmacist Interventions Intended to Prevent and Solve Negative Outcomes Associated with Medication.
commenting on Hoth AB, Carter BL, Ness J, Bhattacharyya, Shorr RI, Rosenthal GE, Kaboli PJ. Development and Reliability Testing of the Clinical Pharmacist Recommendation Taxonomy. Pharmacotherapy 2007;27(5):639-46.

May 2007

Wiens B, Levine M, Jafari S, Etminan M. Immortal Time Bias in Effects of Lipid Lowering Agents on Pneumonia.
commenting on Schlienger RG, Fedson DS, Jick SS, Jick H, Meier CR. Statins and the Risk of Pneumonia: A Population-Based, Nested Case-Control Study. Pharmacotherapy 2007;27(3):325-332.

Riche DM. Impracticality of Cinnamon Supplements in Diabetes.
commenting on Pham AQ, Kourlas H, Pham DQ. Cinnamon supplementation in patients with type 2 diabetes mellitus. Pharmacotherapy 2007;27(4):595-9.

April 2007

Hubbe M. Pharmacoeconomic Evaluation of Antimuscarinic Agents: Bias toward Solifenacin?
commenting on Ko Y, Malone DC, Armstrong EP. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder. Pharmacotherapy. 2006;26(12):1694-1702.

Gabardi S. Factors Influencing the Magnitude and Clinical Significance of Drug Interactions between Azole Antifungals and Select Immunosuppressants
commenting on Saad AH, Depestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006;26(12):1730-44.

March 2007

Lucas Jr BD, Lucas KH, Reyes BJ. More on NSAIDs and Cardiovascular Risk
commenting on response by Stacy ZA, Dobesh PP, Trujillo TC to Cardiovascular risks of cyclooxygenase inhibition. Pharmacotherapy 2006;26:e125-128.

January 2007

Abanades S, Pardo-Lozano R, Farré M. New Insights on Cefepime Associated Neurotoxicity
commenting on Lam S, Gomolin IH. Cefepime neurotoxicity: Case report, pharmacokinetic considerations, and literature review. Pharmacotherapy. 2006;26(8):1169-74.

November 2006

Krantz MJ, Schmittner J. Pleiotropic Effects of Statin Drugs: Clinical Paradigm or Research Fiction?
commenting on Ito MK, Talbert RL, Tsimikas S. Statin-Associated Pleiotropy: Possible Beneficial Effects Beyond Cholesterol Reduction (Pharmacotherapy 2006;26(7 pt 2):85S-97S.

Lucas Jr BD, Lucas KH, Reyes BJ. Cardiovascular Risks of Cyclooxygenase Inhibition
commenting on Stacy ZA, Dobesh PP, Trujillo TC. Cardiovascular risks of cyclooxygenase inhibition. Pharmacotherapy 2006;26(7):919-38.